Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease

THOUSAND OAKS, Calif., April 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to participate in the World Medical Innovation Forum™ focused on cardiovascular disease held May 1-3, 2017, in Boston. The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. The forum was established to respond to the intensifying transformation of health care and its impact on innovation. This is the third year Amgen has participated in this event as a sponsor.

Four senior leaders from Amgen are scheduled to speak:

• Robert A. Bradway, chairman and chief executive officer, will participate in a fireside chat with Scott Sperling, co-president, Thomas H. Lee Partners. The discussion will highlight Amgen's strategic focus in cardiovascular disease, its commitment to unlocking value through innovative therapeutics that address serious illness, and its approach to innovation. The fireside chat is scheduled for 11:15 a.m. ET on Tuesday, May 2.
• Sean E. Harper, M.D., executive vice president of Research and Development, will participate in a session on "Precision Cardiovascular Medicine: What is Different This Time" moderated by Alex de Winter, Ph.D., managing director, GE Ventures. The conversation will examine the impact of combined phenotypic and genotypic characterization on optimizing response to therapeutics, trial design, improving outcomes, and redefining reimbursement. The session is scheduled for 2 p.m. ET on Tuesday, May 2.
• Scott M. Wasserman, M.D., vice president of Global Development, will present on the "Global Clinical Trials: Next Generation Design and Scalability" panel moderated by Marc Sabatine, M.D., chairman TIMI Study Group, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, Brigham and Women's Hospital. The expert panel members will discuss design and implementation of clinical studies globally, with a focus on strategies for patient access, regulatory implications, cost containment, and management of relationships with global service providers. The panel is scheduled for 1:10 p.m. ET on Tuesday, May 2.
• Aariff Khakoo, M.D., vice president of Cardiometabolic Disorders Research, will present on the "New Targets in Coronary Artery Disease" panel moderated by Sekar Kathiresan, M.D., director of the Center for Human Genetic Research at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School. The expert panel members will review the design and implementation of clinical studies globally, with a focus on strategies for patient access, leveraging electronic health records and mobile device data, personalized medicine, regulatory implications, cost containment, and management of relationships with global service providers. The panel is scheduled for 9:15 a.m. ET on Wednesday, May 3.

The above sessions will take place at The Westin Copley Place in Boston. Mr. Bradway's discussion will be hosted in the GE Ballroom and the other sessions will be held in the Boston Scientific Ballroom.

About Amgen in the Cardiovascular Therapeutic Area
Building on more than three decades of experience in developing biotechnology medicines for patients with serious illnesses, Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.¹ Amgen's research into cardiovascular disease, and potential treatment options, is part of a growing competency at Amgen that utilizes human genetics to identify and validate certain drug targets. Through its own research and development efforts, as well as partnerships, Amgen is building a robust cardiovascular portfolio consisting of several approved and investigational molecules in an effort to address a number of today's important unmet patient needs, such as high cholesterol and heart failure.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT:  Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)

¹ World Health Organization. Cardiovascular diseases (CVDs) fact sheet. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed February 2017.

SOURCE Amgen

Related Links

http://www.amgen.com